Travere Therapeutics
TVTX
119 hedge funds and large institutions have $908M invested in Travere Therapeutics in 2018 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 42 increasing their positions, 38 reducing their positions, and 17 closing their positions.
633% more call options, than puts
Call options by funds: $8.85M | Put options by funds: $1.21M
12% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 17
11% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 38
7% more capital invested
Capital invested by funds: $845M → $908M (+$62.5M)
0.24% more ownership
Funds ownership: 102.02% → 102.26% (+0.24%)
1% less funds holding
Funds holding: 120 → 119 (-1)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$16.4M |
| 2 |
PA
Perceptive Advisors
New York
|
+$12.9M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$11.7M |
| 4 |
Millennium Management
New York
|
+$9.02M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$7.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$18.6M |
| 2 |
BC
Broadfin Capital
New York
|
-$11M |
| 3 |
IPLA
Ice Pond Lane Advisers
New York
|
-$10.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$6.79M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.03M |
TVTX Hedge Fund Activity: Q1 2018 in Review
119 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q1 2018, worth a combined $908M — up 7.4% from $845M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new TVTX positions and 17 closed out — a net gain of 2 holders — while 42 added to existing stakes and 38 trimmed.
The largest buyer was Invesco, adding an estimated $16.4M. The largest seller was Franklin Resources, exiting entirely with an estimated $18.6M sold.
- 119 institutional investors held Travere Therapeutics (TVTX) as of Q1 2018, down from 120 in Q4 2017.
- Funds reported $908M of Travere Therapeutics stock for Q1 2018, up 7.4% quarter-over-quarter.
- 19 funds opened new Travere Therapeutics positions in Q1 2018 and 17 closed out, a net change of +2 holders.
- The largest Travere Therapeutics buyer in Q1 2018 was Invesco, an estimated $16.4M added.
- The largest Travere Therapeutics seller in Q1 2018 was Franklin Resources, an estimated $18.6M sold.
Based on aggregated 13F filings for Q1 2018.